Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma.

ABSTRACT: Glioblastoma multiforme (GBM) is the most aggressive and common primary central nervous system tumour. Despite extensive therapy, GBM patients usually have poor prognosis with a median survival of 12-15 months. Novel molecular biomarkers that can improve survival prediction and help with treatment strategies are still urgently required. Here we aimed to robustly identify a gene signature panel for improved survival prediction in primary GBM patients. We identified 2166 differentially expressed genes (DEGs) using meta-analysis of microarray datasets comprising of 955 samples (biggest primary GBM cohort for such studies as per our knowledge) and 3368 DEGs from RNA-seq dataset with 165 samples. Based on the 1443 common DEGs, using univariate Cox and least absolute shrinkage and selection oper

SUBMITTER: Prasad B 

PROVIDER: S-EPMC7541357 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature